How much does Blinatumomab cost?

Blinatumomab is a revolutionary biologic agent used to treat acute lymphoblastic leukemia (Acute Lymphoblastic Leukemia, ALL), specifically B cell acute lymphoblastic leukemia. What makes this drug unique is its mechanism of action and its dramatic effect in improving the treatment of leukemia.

Belintuzumab has been launched in China, but it has not yet been included in medical insurance. The domestic price is about 10,000 yuan. Please consult the local hospital pharmacy for specific prices.

Belintuzumab is a type of chimeric T cell receptor (CAR-T) therapy. Its mechanism of action is to achieve precise positioning and attack of leukemia cells by connecting CD3positive T cells and CD19positive B cells. This allows the immune system to more effectively destroy leukemia cells without causing significant damage to normal cells. This targeted approach greatly improves treatment effectiveness, especially for patients who have developed resistance to traditional treatments.

In terms of clinical application, belintuzumab has been widely used in the treatment of relapsed or refractory Bcell acute lymphoblastic leukemia. Clinical trial results show that it can achieve a response rate of up to 80%, providing patients with a new chance of survival. In addition, compared with traditional leukemia treatments, belintuzumab has relatively mild side effects, including general reactions such as fever, headache, and nausea.

Belintuzumab represents an innovation in leukemia treatment, bringing new treatment options to patients and improving their quality of life and survival. The therapy's success has also spurred research interest in its potential use in treating other types of leukemia and lymphoma. Through continuous research and development, belintuzumab is expected to bring new breakthroughs and hope for the treatment of a wider range of cancer types and malignant diseases.